Effect of a brief cognitive-behavioral group intervention during rehabilitation for women with breast cancer
Not Applicable
Completed
- Conditions
- C50Malignant neoplasm of breast
- Registration Number
- DRKS00017571
- Lead Sponsor
- VAMED Rehaklinik Ahrenshoop GmbH
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 160
Inclusion Criteria
We include women with breast cancer (tumor stage I-IV) undergoing rehabilitation having a score of at least 5 points on the distress thermometer.
Exclusion Criteria
We exclude female patients already receiving psychiatric treatment or psychotherapy. We also exclude female patients with ductal carcinoma in situ.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary outcome is the anxiety score measured by the Hospital Anxiety and Depressions Scale (HADS). The HADS is a questionnaire for the self-report of depression and anxiety which was developed for patients with physical illness (Zigmond and Snaith 1983). The anxiety module of the HADS consists of 7 items. Symptoms of anxiety during a period of one week are scored with 0 to 3 points. The total score ranges from 0 to 21 points. The level of anxiety is assessed at the beginning and the end of the rehabilitation program and 12 weeks after completing the program. The primary endpoint is the 12-week measurement.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways are modulated by cognitive-behavioral therapy in breast cancer rehabilitation?
How does brief cognitive-behavioral group intervention compare to standard psychosocial care for C50 breast cancer survivors?
Which biomarkers correlate with psychological outcomes in cognitive-behavioral interventions for breast cancer patients?
What adverse events are associated with group-based cognitive-behavioral therapy during oncology rehabilitation?
Are there synergistic effects when combining cognitive-behavioral therapy with pharmacological treatments for breast cancer-related distress?